Clinical trial
Beta Alethine in Treating Patients With Myeloma
NCT00006466 · LifeTime Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00006466 |
|---|---|
| Title | Beta Alethine in Treating Patients With Myeloma |
| Official title | Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma |
| Lead sponsor | LifeTime Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition |
| Intervention type | Drug |
| Interventions | beta alethine |
| Start date | Aug 1, 2000 |
| First posted | Oct 8, 2003 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: